Advancing type 1 diabetes therapy: autologous islet transplant breakthrough  

作　　者：Ram Abou Zaki Assam El-Osta 

机构地区：[1]Baker Heart and Diabetes Institute,Epigenetics in Human Health and Disease Program,Melbourne,VIC,Australia [2]Baker Department of Cardiometabolic Health,The University of Melbourne,Parkville,VIC,Australia [3]School of Translational Medicine,Department of Diabetes,Monash University,Melbourne,VIC,Australia [4]Department of Medicine and Therapeutics,The Chinese University of Hong Kong(CUHK),Hong Kong SAR,China

出　　处：《Signal Transduction and Targeted Therapy》2025年第1期15-17,共3页信号转导与靶向治疗(英文)

基　　金：funded through a strategic research agreement with JDRF International(grant 2-SRA-2024-1442-S-B);received additional support from a grant provided by the Danish Diabetes Academy to AEO,which is financed by the Novo Nordisk Foundation(grant NNF17SA0031406).

摘　　要：The first patient to receive autologous transplantation of chemically induced pluripotent stem-cell-derived islets(CiPSC islets)was recently announced in the journal Cell.The breakthrough surgery by Wang and colleagues at Nankai University,achieved year-long insulin independence for an adult living with type 1 diabetes(T1D).

关 键 词：AUTOLOGOUS ISLET DIABETES 

分 类 号：R58[医药卫生—内分泌]